Global Colorectal Cancer Diagnostics Market Estimated to Record Highest CAGR by 2017 to 2022 with Market players- Illumina Inc, Sysmex Corporation, Danaher Corporation, Rosetta Genomics, Epigenomics AG, Exact Science Corporation, Pathway Genomics Corporat

Colorectal cancer diagnostics are a wide range of screening tests and diagnosis procedures that are employed before treating a patient with colon cancer. A typical diagnosis of colorectal cancer consists of tests such as colonoscopy, biopsy, blood sample testing, CT scan, ultrasound, MRI and molecular testing of the growing tumor. 

Request 100 Page Sample Report Now: https://www.factmr.com/connectus/sample?flag=S&rep_id=70

A recent report by Fact.MR projects the global Colorectal Cancer Diagnostics Market to register an impressive expansion at 8.5% CAGR during the forecast period 2017 to 2022. Revenues from the global colorectal cancer diagnostics market is expected to surpass US$ 2,000 Mn by 2022-end.

Surging Unmet Requirements for Colorectal Cancer Diagnostics in Emerging Economies to Pave Growth Opportunities for Market Players

The emergence of new improved diagnosis tests, soaring uptakes of diagnosis-associated therapies, and increasing initiatives by private and government organisations are factors likely to fuel growth of the global colorectal cancer diagnostics market. Surging unmet requirements for colorectal cancer diagnostics around many emerging economies, along with the shortage of neoadjuvant as well as adjuvant pipeline agents for diagnosing high-risk patients suffering from resectable colorectal cancer is anticipated to pave tremendous growth opportunities for global leaders in the market. In contrast, factors such as rising patient reluctance against medications of colorectal cancer, and absence of awareness about therapeutics and diagnostics of colorectal cancer in many remote regions around the world is estimated to impede the market growth.

Introduction of Effective Diagnosis Tests and Development of Screening Methods to Drive the Market Growth

The World Cancer Research Fund estimates the colorectal cancer to be the third-most occurring form of cancer around the world. In 2012, more than 1 Mn people were diagnosed with colorectal cancer. Majority of these were reported in the developed economies, and this is anticipated to surge in the near future. These incidences of colorectal cancer have boosted demand for their diagnostics worldwide. In addition, the number of deaths caused by colorectal cancer has witnessed a decline over the recent past, on the back of awareness spread by American Cancer Society (ACS). Introduction of effective instruments, along with the development of screening methods are estimated to further propel growth of the global market for colorectal cancer diagnostics.

The market for colorectal cancer diagnostics in Asia Pacific excluding Japan (APEJ) is estimated to exhibit the fastest expansion throughout the forecast period. Revenue from the market in Middle East & Africa (MEA) will continue to be sluggish during the forecast period. North America will remain the most lucrative region for colorectal cancer diagnostics. North America’s colorectal cancer diagnostics market is anticipated to account for nearly US$ 800 Mn in revenues by 2022-end. Markets in Europe and North America are estimated to register a parallel expansion at a CAGR of 8.6% through 2022.

Get Access To TOC Covering 200+ Topics: https://www.factmr.com/report/70/colorectal-cancer-diagnostics-market

FOB Tests will Continue to Witness Largest Adoption for Colorectal Cancer Diagnostics

FOB tests will remain the largest adopted tests for colorectal cancer diagnostics across the globe. In addition, FOB tests in the global colorectal cancer diagnostics market will account for the largest revenues, followed by CTC tests. The immunochemistry tests will register the highest CAGR in the market through 2022. However, BRAF tests will account for the lowest revenues in the global market for colorectal cancer diagnostics throughout the forecast period.

Based on end-users, even though hospital-associated labs are estimated to remain sought-after for colorectal cancer diagnostics, cancer research institutes will register the fastest expansion through 2022. Hospital-associated labs in the global colorectal cancer diagnostics market are estimated to account for nearly US$ 1,000 Mn in revenues by 2022-end. In addition, independent diagnostic laboratories will remain the second largest end-users of colorectal cancer diagnostics in the global market.

Competition Tracking

The report has also profiled prominent players in the global market for colorectal cancer diagnostics, which include Illumina, Inc, Sysmex Corporation, Danaher Corporation, Rosetta Genomics, Epigenomics AG, Exact Science Corporation, Pathway Genomics Corporation, Biocept, Inc., Cancer Genetics, Inc, and Foundation Medicine, Inc

Ask Industry Expert about this Report: https://www.factmr.com/connectus/sample?flag=AE&rep_id=70

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Blog: https://factmrblog.com/
Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.